Brief: Autolus Therapeutics Collaborates With Cabaletta Bio For Autoimmune Disease Cell Therapies
09/01/2023 13:43
Jan 9 (Reuters) - Autolus Therapeutics PLC AUTL.O :
* AUTOLUS THERAPEUTICS ANNOUNCES COLLABORATION WITH
CABALETTA BIO
FOR USE OF AUTOLUS’ SAFETY SWITCH SYSTEM IN CELL THERAPIES FOR
AUTOIMMUNE DISEASE
* AUTOLUS-IN DEAL,CO WILL RECEIVE UPFRONT PAYMENT FOR
NON-EXCLUSIVE ACCESS TO RQR8 SAFETY SWITCH FOR USE IN
CABALETTA'S CD19-CAR T CELL THERAPY PROGRAM
* AUTOLUS THERAPEUTICS PLC - IS ENTITLED TO RECEIVE
ROYALTIES ON
NET SALES OF ALL CABALETTA CELL THERAPY PRODUCTS THAT
INCORPORATE RQR8 SAFETY SWITCH
Source text for Eikon: ID:nGNX6pWZ6P
Further company coverage: AUTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants